OBJECTIVES: Combination chemotherapy regimens have shown promising results in patients with metastatic colorectal cancer. However, only very few studies have studied the effect of palliative chemotherapy in peritoneal carcinomatosis (PC) and no data are present incorporating biological therapies in the treatment of PC in colorectal cancer. METHODS: By means of merging with the regional Eindhoven Cancer Registry, all consecutive patients diagnosed with synchronous PC of colorectal origin since the year 2000 treated with palliative chemotherapy in our hospital were included. Data on chemotherapeutic agents used were collected retrospectively. The effect of biological therapies on survival was investigated. RESULTS: Fifty consecutive patients were included. Chemotherapeutic treatment consisted mainly of 5-fluorouracil-based chemotherapy with oxaliplatin. In 22 patients biological therapies were added. Overall survival was 12.5 months [95% confidence interval (CI), 9.2-15.5]. In patients receiving chemotherapy in combination with a biological therapy, overall survival was significantly prolonged as compared with those treated without (18.2 months, 95% CI, 9.5-27.0 vs. 10.1 mo, 95% CI, 6.2-14.1, respectively; P=0.001). Prolongation of survival of patients receiving biological therapies in first-line treatment was even more pronounced, being 22.4 months (95% CI, 15.0-29.5). Similar effects were observed on progression-free survival. CONCLUSIONS: Systemic chemotherapy, once regarded as futile in patients suffering from PC, resulted in an overall survival of 12 months in this unselected group of PC-patients. Addition of biological therapies in the first line of treatment prolonged overall survival to 22.4 months. Although the results of this small study should be interpreted with caution, this promising finding warrants further research.
OBJECTIVES: Combination chemotherapy regimens have shown promising results in patients with metastatic colorectal cancer. However, only very few studies have studied the effect of palliative chemotherapy in peritoneal carcinomatosis (PC) and no data are present incorporating biological therapies in the treatment of PC in colorectal cancer. METHODS: By means of merging with the regional Eindhoven Cancer Registry, all consecutive patients diagnosed with synchronous PC of colorectal origin since the year 2000 treated with palliative chemotherapy in our hospital were included. Data on chemotherapeutic agents used were collected retrospectively. The effect of biological therapies on survival was investigated. RESULTS: Fifty consecutive patients were included. Chemotherapeutic treatment consisted mainly of 5-fluorouracil-based chemotherapy with oxaliplatin. In 22 patients biological therapies were added. Overall survival was 12.5 months [95% confidence interval (CI), 9.2-15.5]. In patients receiving chemotherapy in combination with a biological therapy, overall survival was significantly prolonged as compared with those treated without (18.2 months, 95% CI, 9.5-27.0 vs. 10.1 mo, 95% CI, 6.2-14.1, respectively; P=0.001). Prolongation of survival of patients receiving biological therapies in first-line treatment was even more pronounced, being 22.4 months (95% CI, 15.0-29.5). Similar effects were observed on progression-free survival. CONCLUSIONS: Systemic chemotherapy, once regarded as futile in patients suffering from PC, resulted in an overall survival of 12 months in this unselected group of PC-patients. Addition of biological therapies in the first line of treatment prolonged overall survival to 22.4 months. Although the results of this small study should be interpreted with caution, this promising finding warrants further research.
Authors: H Ishida; K Kumamoto; K Ishibashi; S Hatano; T Matsuzawa; N Okada; Y Kumagai; H Baba; N Haga Journal: Tech Coloproctol Date: 2013-02-07 Impact factor: 3.781
Authors: Yvonne L B Klaver; Valery E P P Lemmens; Simon W Nienhuijs; Misha D P Luyer; Ignace H J T de Hingh Journal: World J Gastroenterol Date: 2012-10-21 Impact factor: 5.742
Authors: N R Sluiter; E M V de Cuba; R Kwakman; W J H J Meijerink; P M Delis-van Diemen; V M H Coupé; J A M Beliën; G A Meijer; I H J T de Hingh; E A te Velde Journal: Clin Exp Metastasis Date: 2016-02-12 Impact factor: 5.150
Authors: E M V de Cuba; I H J T de Hingh; N R Sluiter; R Kwakman; V M H Coupé; J A M Beliën; V J Verwaal; W J H J Meijerink; P M Delis-van Diemen; H J Bonjer; G A Meijer; E A Te Velde Journal: Ann Surg Oncol Date: 2016-01-04 Impact factor: 5.344
Authors: T R van Oudheusden; L G Razenberg; Y R van Gestel; G J Creemers; V E Lemmens; I H de Hingh Journal: Sci Rep Date: 2015-12-21 Impact factor: 4.379